Form D · Other Technology

Arpeggio Biosciences, Inc.

Boulder, CO · CIK 0001786698

Offering snapshot reported Nov 24, 2025 · SEC filing

Reported sold
$20M
Offering amount: $35.3M
Investors reported
12
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Nov 12, 2025
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Nov 24, 2025Initial$20,037,075No comparison12SEC filing
Mar 27, 2025Initial$4,026,774No comparison14SEC filing
Sep 23, 2022Initial$20,248,534No comparison28SEC filing
Sep 6, 2019Initial$1,970,000No comparison5SEC filing
Aug 29, 2019Initial$125,000No comparison1SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-564924

Source: Form D, filed Nov 24, 2025. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
David Allison Director
Joseph G. Azofeifa Director, Executive
Mira Chaurushiya Director
Robin D. Dowell Deen Promoter
Samuel Kintz Director
Eric Martin Executive
Joe Mc Mahon Director
Amit Mehta Director
Laura Norris Executive
Timothy Read Executive
Aaron Royston Director
Daniel Weaver Promoter

Issuer details

Industry: Other Technology (See others in industry)

Address:
4888 Pearl East Circle Suite 110 E
Boulder, CO, 80301